GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults

D B Allen; P Backeljauw; M Bidlingmaier; B M K Biller; M Boguszewski; P Burman; Graham Butler; K Chihara; J Christiansen; S Cianfarani; P Clayton; D Clemmons; P Cohen; F Darendeliler; C Deal; D Dunger; E M Erfurth; J S Fuqua; A Grimberg; M Haymond; C Higham; K Ho; A R Hoffman; A Hokken-Koelega; G Johannsson; A Juul; J Kopchick; P Lee; M Pollak; S Radovick; L Robison; R Rosenfeld; R J Ross; L Savendahl; P Saenger; H Toft Sorensen; K Stochholm; C Strasburger; A Swerdlow; M Thorner

doi:10.1530/EJE-15-0873

GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults

D B Allen, P Backeljauw, M Bidlingmaier, B M K Biller, M Boguszewski, P Burman, Graham Butler, K Chihara, J Christiansen, S Cianfarani, P Clayton, D Clemmons, P Cohen, F Darendeliler, C Deal, D Dunger, E M Erfurth, J S Fuqua, A Grimberg, M HaymondC Higham, K Ho, A R Hoffman, A Hokken-Koelega, G Johannsson, A Juul, J Kopchick, P Lee, M Pollak, S Radovick, L Robison, R Rosenfeld, R J Ross, L Savendahl, P Saenger, H Toft Sorensen, K Stochholm, C Strasburger, A Swerdlow, M Thorner

Afdeling for Vækst og Reproduktion

184 Citationer (Scopus)

Abstract

Recombinant human GH (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that 'for approved indications, GH is safe'; however, the statement highlighted a number of areas for on-going surveillance of long-term safety, including cancer risk, impact on glucose homeostasis, and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk, and the need for long-term surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS, and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement.

Originalsprog	Engelsk
Tidsskrift	European journal of endocrinology / European Federation of Endocrine Societies
Vol/bind	174
Udgave nummer	2
Sider (fra-til)	P1-9
ISSN	0804-4643
DOI	https://doi.org/10.1530/EJE-15-0873
Status	Udgivet - feb. 2015

Adgang til dokumentet

10.1530/EJE-15-0873

Citationsformater

Allen, D. B., Backeljauw, P., Bidlingmaier, M., Biller, B. M. K., Boguszewski, M., Burman, P., Butler, G., Chihara, K., Christiansen, J., Cianfarani, S., Clayton, P., Clemmons, D., Cohen, P., Darendeliler, F., Deal, C., Dunger, D., Erfurth, E. M., Fuqua, J. S., Grimberg, A., ... Thorner, M. (2015). GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. European journal of endocrinology / European Federation of Endocrine Societies, 174(2), P1-9. https://doi.org/10.1530/EJE-15-0873

Allen, DB, Backeljauw, P, Bidlingmaier, M, Biller, BMK, Boguszewski, M, Burman, P, Butler, G, Chihara, K, Christiansen, J, Cianfarani, S, Clayton, P, Clemmons, D, Cohen, P, Darendeliler, F, Deal, C, Dunger, D, Erfurth, EM, Fuqua, JS, Grimberg, A, Haymond, M, Higham, C, Ho, K, Hoffman, AR, Hokken-Koelega, A, Johannsson, G, Juul, A, Kopchick, J, Lee, P, Pollak, M, Radovick, S, Robison, L, Rosenfeld, R, Ross, RJ, Savendahl, L, Saenger, P, Toft Sorensen, H, Stochholm, K, Strasburger, C, Swerdlow, A & Thorner, M 2015, 'GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults', European journal of endocrinology / European Federation of Endocrine Societies, bind 174, nr. 2, s. P1-9. https://doi.org/10.1530/EJE-15-0873

@article{e51931b69d7b4e5189c7b61448b7a86e,

title = "GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults",

abstract = "Recombinant human GH (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that 'for approved indications, GH is safe'; however, the statement highlighted a number of areas for on-going surveillance of long-term safety, including cancer risk, impact on glucose homeostasis, and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk, and the need for long-term surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS, and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement.",

author = "Allen, {D B} and P Backeljauw and M Bidlingmaier and Biller, {B M K} and M Boguszewski and P Burman and Graham Butler and K Chihara and J Christiansen and S Cianfarani and P Clayton and D Clemmons and P Cohen and F Darendeliler and C Deal and D Dunger and Erfurth, {E M} and Fuqua, {J S} and A Grimberg and M Haymond and C Higham and K Ho and Hoffman, {A R} and A Hokken-Koelega and G Johannsson and A Juul and J Kopchick and P Lee and M Pollak and S Radovick and L Robison and R Rosenfeld and Ross, {R J} and L Savendahl and P Saenger and {Toft Sorensen}, H and K Stochholm and C Strasburger and A Swerdlow and M Thorner",

note = "{\textcopyright} 2016 The authors.",

year = "2015",

month = feb,

doi = "10.1530/EJE-15-0873",

language = "English",

volume = "174",

pages = "P1--9",

journal = "European journal of endocrinology / European Federation of Endocrine Societies",

issn = "0804-4643",

publisher = "BioScientifica Ltd",

number = "2",

}

TY - JOUR

T1 - GH safety workshop position paper

T2 - a critical appraisal of recombinant human GH therapy in children and adults

AU - Allen, D B

AU - Backeljauw, P

AU - Bidlingmaier, M

AU - Biller, B M K

AU - Boguszewski, M

AU - Burman, P

AU - Butler, Graham

AU - Chihara, K

AU - Christiansen, J

AU - Cianfarani, S

AU - Clayton, P

AU - Clemmons, D

AU - Cohen, P

AU - Darendeliler, F

AU - Deal, C

AU - Dunger, D

AU - Erfurth, E M

AU - Fuqua, J S

AU - Grimberg, A

AU - Haymond, M

AU - Higham, C

AU - Ho, K

AU - Hoffman, A R

AU - Hokken-Koelega, A

AU - Johannsson, G

AU - Juul, A

AU - Kopchick, J

AU - Lee, P

AU - Pollak, M

AU - Radovick, S

AU - Robison, L

AU - Rosenfeld, R

AU - Ross, R J

AU - Savendahl, L

AU - Saenger, P

AU - Toft Sorensen, H

AU - Stochholm, K

AU - Strasburger, C

AU - Swerdlow, A

AU - Thorner, M

PY - 2015/2

Y1 - 2015/2

N2 - Recombinant human GH (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that 'for approved indications, GH is safe'; however, the statement highlighted a number of areas for on-going surveillance of long-term safety, including cancer risk, impact on glucose homeostasis, and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk, and the need for long-term surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS, and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement.

AB - Recombinant human GH (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that 'for approved indications, GH is safe'; however, the statement highlighted a number of areas for on-going surveillance of long-term safety, including cancer risk, impact on glucose homeostasis, and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk, and the need for long-term surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS, and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement.

U2 - 10.1530/EJE-15-0873

DO - 10.1530/EJE-15-0873

M3 - Journal article

C2 - 26563978

SN - 0804-4643

VL - 174

SP - P1-9

JO - European journal of endocrinology / European Federation of Endocrine Societies

JF - European journal of endocrinology / European Federation of Endocrine Societies

IS - 2

ER -

GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater